title: Pharmacological and clinical studies of the antiandrogen Anandron.
abstract: This paper summarizes the animal and human studies with Anandron available at the time of the meeting. The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic androgen receptor, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens. Thus, as shown in 4 different double blind studies performed in stage D2 prostrate cancer patients, the combination of Anandron with surgical or chemical castration enhanced the beneficial effects of castration alone and thus seems a step forward in the hormonal treatment of prostatic carcinoma.
authors.affiliation: Centre de Recherches Roussel Uclaf, Romainville, France.
authors.forename: M
authors.initials: M
authors.lastname: Moguilewsky
authors.forename: C
authors.initials: C
authors.lastname: Bertagna
authors.forename: M
authors.initials: M
authors.lastname: Hucher
mesh_terms: D000726:Androgen Antagonists; D000818:Animals; D003131:Combined Modality Therapy; D006801:Humans; D007093:Imidazoles / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D048289:Imidazolidines; D008297:Male; D009919:Orchiectomy; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy; D051381:Rats; D011944:Receptors, Androgen / Q000378:metabolism; D013739:Testosterone / Q000037:antagonists & inhibitors
chemical_list: D000726:Androgen Antagonists; D007093:Imidazoles; D048289:Imidazolidines; D011944:Receptors, Androgen; D013739:Testosterone; C021277:nilutamide